Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 12, 2025

InVivoMab anti-human CD8?

RRID:AB_1107673
Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0004-2, RRID:AB_1107673)

Antibody Information

URL: http://antibodyregistry.org/AB_1107673

Proper Citation: (Bio X Cell Cat# BE0004-2, RRID:AB_1107673)

Target Antigen: CD8?

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: in vivo CD8+ T cell depletion in humanized mice

Antibody Name: InVivoMab anti-human CD8?

Description: This monoclonal targets CD8?

Target Organism: human

Clone ID: clone OKT-8

Antibody ID: AB_1107673

Vendor: Bio X Cell

Catalog Number: BE0004-2

Alternative Catalog Numbers: BE0004-2-25MG, BE0004-2-50MG, BE0004-2-5MG, BE0004-2-1MG, BE0004-2-100MG

Record Creation Time: 20231110T061451+0000

Record Last Update: 20241115T121950+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-human CD8?.

No alerts have been found for InVivoMab anti-human CD8?.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Liu T, et al. (2024) An axon-T cell feedback loop enhances inflammation and axon degeneration. Cell reports, 43(2), 113721.

Deng S, et al. (2024) ITPRIPL1 binds CD3? to impede T cell activation and enable tumor immune evasion. Cell, 187(9), 2305.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. Cancer immunology research, 12(4), 491.

Ma X, et al. (2023) Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-? axis. Cell reports, 42(8), 112944.

Ramachandran M, et al. (2023) Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma. Cancer cell, 41(6), 1134.